DTPA(DOTA)-Nimotuzumab Radiolabeling with Generator-Produced Thorium for Radioimmunotherapy of EGFR-Overexpressing Carcinomas.

M G BravoB V EgorovaA N VasilievE V LapshinaS V ErmolaevM O Durymanov

Published in: Current radiopharmaceuticals (2023)

The molar ratios of Th:BFCA of 1:5000 for p-SCN-Bn-DOTA and 1:100 for p-SCN-Bn-DTPA were found to be optimal and resulted in 86-90% RCY for both BFCAs complexes. Thorium-234 incorporation into both radioimmunoconjugates reached 45-50%. It has been shown that Th-DTPA-Nimotuzumab radioimmunoconjugate specifically bound with EGFR overexpressing epidermoid carcinoma A431 cells.

Keyphrases

small cell lung cancer
pet ct
epidermal growth factor receptor
tyrosine kinase
pet imaging
induced apoptosis
cell cycle arrest
high grade
signaling pathway
oxidative stress
computed tomography
positron emission tomography